Results 101 to 110 of about 183,958 (171)

Evaluating Sarcoid-Like Reactions in Melanoma Patients Treated With Pembrolizumab: A Systematic Review. [PDF]

Cureus
Khan H, Mohamed F, Wafiy J, Shah A, Kolawole AO, Bobier C.   +5 more
europepmc   +1 more source

Exceptional Response to a Single Dose of Pembrolizumab as Salvage Therapy for Metastatic Adrenocortical Carcinoma. [PDF]

JCEM Case Rep
Branchaud-Croisetière L, Turcotte E, Castilloux JF, Bourdeau I, Mercier F, St-Jean M.   +5 more
europepmc   +1 more source

Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E trials. [PDF]

Gynecol Oncol Rep
Francoeur AA, Liang SY, File B, Choi E, Brameld M, Richardson MT, Johnson CR, Kapp DS, Tewari KS, Chan JK.   +9 more
europepmc   +1 more source

Molecular and immune biomarker testing in squamous-cell lung cancer: Effect of current and future therapies and technologies [PDF]

, 2018
Bradley, Jeffrey D, et al,
core   +1 more source

A Case of Upper Tract Urothelial Carcinoma With Neuroendocrine Differentiation Successfully Treated With Enfortumab Vedotin and Pembrolizumab. [PDF]

IJU Case Rep
Taniguchi K, Hashimoto M, Nakayama T, Fujimoto S, Toyoda S, Kikuchi T, Velasco MA, Maenishi O, Minami T, Fujita K.   +9 more
europepmc   +1 more source

Complete locoregional response to radiotherapy and pembrolizumab in an elderly and frail patient with oropharyngeal squamous cell carcinoma: A case report. [PDF]

Medicine (Baltimore)
Zoboli FB, Mosca M, Gagliano A, Laghi V, Siepe G, Rihawi K, Nobili E, Filippini DM.   +7 more
europepmc   +1 more source

Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma. [PDF]

ESMO Open
Shitara K, Bang YJ, Wyrwicz LS, Rha SY, Oshima T, Pietrantonio F, Park YK, Lonardi S, Yañez P, Yen CJ, Metges JP, Garrido M, Moehler M, Pelles-Avraham S, Yong WP, Spallanzani A, Jensen E, Krishnan R, Shih CS, Al-Batran SE.   +19 more
europepmc   +1 more source

A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma. [PDF]

Oncoimmunology
Lambert C, Jamal R, Thébault P, Cocolakis E, Bélanger K, Dionne J, Cailhier JF, Le H, Letendre C, Lepage S, Shechtman Y, Lapointe R, Miller WH.   +12 more
europepmc   +1 more source

Real-world experience with first-line pembrolizumab plus chemotherapy in Vietnamese patients with stage IV esophageal squamous cell carcinoma. [PDF]

Front Immunol
Van Tran T, Nguyen PT, Van Le Q, Nguyen GHT, Le Trinh H, Le KH, Hoang GN.   +6 more
europepmc   +1 more source

Immunotherapy response in microsatellite-stable poorly differentiated thyroid carcinoma with mismatch repair deficiency and high tumor mutational burden. [PDF]

Arch Endocrinol Metab
Feldmann JH, Feldmann JF, Hidalgo-Filho CM, Alves GLC, Vilela RS, Gonçalves S, Castro Júnior G.   +6 more
europepmc   +1 more source